World's Best Scientists 2026 revealed!
Philippe Guillaume

Philippe Guillaume

D-Index & Metrics

Immunology

D-Index
62
Citations
11583
World Ranking
3167
National Ranking
77

Philippe Guillaume publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Philippe Guillaume sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 126 publications — 8th percentile

8% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Philippe Guillaume D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Philippe Guillaume sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 62 D-Index — 37th percentile

37% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Philippe Guillaume is affiliated with Ludwig Cancer Research in Belgium, contributing extensively to the fields of medicine, immunology, microbiology, and molecular biology. Their research primarily centers on immunotherapy and immune responses, CAR-T cell therapy, vaccines and immunoinformatics approaches, T-cell and B-cell immunology, cancer immunotherapy and biomarkers, immune cell function and interaction, as well as single-cell and spatial transcriptomics.

Their recent publications include:

  • "Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer," 2021, Science Advances
  • "Machine learning predictions of MHC-II specificities reveal alternative binding mode of class II epitopes," 2023, Immunity
  • "Sensitive identification of neoantigens and cognate TCRs in human solid tumors," 2021, Nature Biotechnology
  • "Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8+ T-cell epitopes," 2023, Cell Systems
  • "Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors," 2023, Nature Communications

Guillaume frequently publishes in the following venues:

  • bioRxiv (Cold Spring Harbor Laboratory)
  • Science Advances
  • Frontiers in Immunology
  • Journal for ImmunoTherapy of Cancer
  • iScience

The scientist collaborates regularly with a core group of co-authors, including:

  • Julien Schmidt
  • Alexandre Harari
  • David Gfeller
  • George Coukos
  • Raphaël Genolet

Their work covers several key areas within medicine and biology, with a focus on immunology and oncology. The subfields relevant to their research include immunology, oncology, molecular biology, psychiatry and mental health, and genetics.

Philippe Guillaume's investigations often explore core topics such as immunotherapy and immune responses, advancing CAR-T cell therapy research, and developing vaccines and immunoinformatics approaches. Their research also involves studying T-cell and B-cell immunology, identifying cancer immunotherapy biomarkers, analyzing immune cell function and interaction, and utilizing single-cell and spatial transcriptomics methodologies.

Best Publications

  • Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen–specific CD8+ T cell dysfunction in melanoma patients

    Julien Fourcade;Zhaojun Sun;Mourad Benallaoua;Philippe Guillaume

  • Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance

    Alfred Zippelius;Pascal Batard;Verena Rubio-Godoy;Gilles Bioley

  • CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1

    Julien Fourcade;Zhaojun Sun;Ornella Pagliano;Philippe Guillaume

  • Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer

    Amélie Cachot;Mariia Bilous;Mariia Bilous;Yen-Cheng Liu;Xiaokang Li

  • Deciphering HLA-I motifs across HLA peptidomes improves neo-antigen predictions and identifies allostery regulating HLA specificity.

    Michal Bassani-Sternberg;Chloé Chong;Chloé Chong;Philippe Guillaume;Philippe Guillaume;Marthe Solleder;Marthe Solleder

  • Robust prediction of HLA class II epitopes by deep motif deconvolution of immunopeptidomes.

    Julien Racle;Justine Michaux;Georg Alexander Rockinger;Marion Arnaud

  • RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.

    Michael Schmitt;Anita Schmitt;Markus T. Rojewski;Jinfei Chen

  • PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen–Specific CD8+ T Cells Induced by Melanoma Vaccines

    Julien Fourcade;Zhaojun Sun;Ornella Pagliano;Joe Marc Chauvin

  • Cis association of Ly49A with MHC class I restricts natural killer cell inhibition.

    Marie-Agnès Doucey;Léonardo Scarpellino;Jacques Zimmer;Philippe Guillaume

  • PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients

    Julien Fourcade;Pavol Kudela;Zhaojun Sun;Hongmei Shen

  • CpG Are Efficient Adjuvants for Specific CTL Induction Against Tumor Antigen-Derived Peptide

    Isabelle Miconnet;Sylvain Koenig;Daniel Speiser;Arthur Krieg;Arthur Krieg

  • Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

    Pedro Romero;Danila Valmori;Mikael J. Pittet;Alfred Zippelius

  • Thymic selection generates a large T cell pool recognizing a self-peptide in humans.

    Alfred Zippelius;Mikaël J. Pittet;Pascal Batard;Nathalie Rufer

  • Cooperation of human tumor-reactive CD4 + and CD8 + T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR

    Jürgen Kuball;Frank W. Schmitz;Ralf Holger Voss;Edite Antunes Ferreira

  • New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site.

    Victor Appay;Camilla Jandus;Verena Voelter;Severine Reynard

  • In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8 + T cell responses

    Christoph Esslinger;Laurence Chapatte;Daniela Finke;Isabelle Miconnet

  • Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia

    Jochen Greiner;Yoko Ono;Yoko Ono;Susanne Hofmann;Anita Schmitt;Anita Schmitt

  • High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy

    David-Alexandre Gross;Stéphanie Graff-Dubois;Paule Opolon;Sébastien Cornet

  • The Length Distribution and Multiple Specificity of Naturally Presented HLA-I Ligands.

    David Gfeller;David Gfeller;Philippe Guillaume;Justine Michaux;Hui-Song Pak

  • Interplay between T Cell Receptor Binding Kinetics and the Level of Cognate Peptide Presented by Major Histocompatibility Complexes Governs CD8+ T Cell Responsiveness

    Melita Irving;Vincent Zoete;Michael Hebeisen;Daphné Schmid

  • Proteasome-assisted identification of a SSX-2-derived epitope recognized by tumor-reactive CTL infiltrating metastatic melanoma.

    Maha Ayyoub;Stefan Stevanovic;Ugur Sahin;Philippe Guillaume

Frequent Co-Authors

Immanuel F. Luescher
Immanuel F. Luescher University of Lausanne
Pedro Romero
Pedro Romero University of Lausanne
Daniel E. Speiser
Daniel E. Speiser University of Lausanne
Jean-Charles Cerottini
Jean-Charles Cerottini University of Lausanne
Danila Valmori
Danila Valmori University of Nantes
David Gfeller
David Gfeller University of Lausanne
George Coukos
George Coukos Cornell University
Mikael J. Pittet
Mikael J. Pittet University of Geneva
Nathalie Rufer
Nathalie Rufer University Hospital of Lausanne
Olivier Michielin
Olivier Michielin University of Lausanne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, exploring related healthcare degrees can broaden career prospects. Programs like the best online psychiatric mental health nurse practitioner programs combine clinical skills with specialized care, offering strong placement opportunities for graduates.

Cost is often a major consideration when selecting a program. The cheapest psych np programs provide quality education at a lower price point, making advanced nursing degrees more accessible to a wider range of students.

Understanding financial outcomes is equally important. The dnp salary by state offers valuable insights into earning potential across different regions, helping students plan their career paths more strategically.

For Registered Nurses looking to expand their expertise, transitioning through an online Ongoing Program can be a practical option. Programs like the fnp to acnp bridge program online enable smooth progression from a Family Nurse Practitioner to an Acute Care Nurse Practitioner role.

These pathways illustrate how combining immunology knowledge with advanced nursing degrees can lead to rewarding careers in healthcare, balancing education quality, cost, and professional growth.

Best Scientists Citing Philippe Guillaume

Trending Scientists

Recently Published Articles